(MedPage Today) — The use of bispecific antibodies (BsAb) before chimeric antigen receptor T-cell therapy (CAR-T) appeared to be a more optimal treatment sequence than BsAb after CAR-T in patients with relapsed or refractory large B-cell lymphoma…
Source link : https://www.medpagetoday.com/hematologyoncology/lymphoma/119225
Author :
Publish date : 2025-12-30 21:30:00
Copyright for syndicated content belongs to the linked Source.













